<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02608450</url>
  </required_header>
  <id_info>
    <org_study_id>CB-03-01/25</org_study_id>
    <nct_id>NCT02608450</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25)</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cassiopea SpA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cassiopea SpA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the safety and efficacy of CB-03-01
      cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial
      acne vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success rate in Investigator's Global Assessment (IGA)</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of subjects in each treatment group achieving &quot;success&quot; at Week 12, with &quot;success&quot; defined as an IGA score of &quot;clear (score=0)&quot; or &quot;almost clear (score=1)&quot; and at least a two-point reduction in IGA compared to Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in non-inflammatory lesion counts</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Absolute change from Baseline in non-inflammatory lesion counts in each treatment group at Week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in inflammatory lesion counts</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Absolute change from Baseline in inflammatory lesion counts in each treatment group at Week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total lesion counts</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Absolute change from Baseline in total lesions counts in each treatment group at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in total lesion counts</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Percent change from Baseline in total lesions counts in each treatment group at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in non-inflammatory lesion counts</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Percent change from Baseline in non-inflammatory lesions count in each treatment group at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in inflammatory lesion counts</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Percent change from Baseline in inflammatory lesions count in each treatment group at Week 12.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Local Site Reactions</measure>
    <time_frame>Baseline, Weeks 4, 8, and 12</time_frame>
    <description>Local Site Reactions (LSRs) including telangiectasia, skin atrophy, striae rubrae, erythema, edema, scaling/dryness, stinging/burning, and pruritus scored by frequency and severity at every visit (Baseline, Weeks 4, 8, and 12).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>CB-03-01 cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CB-03-01 cream, 1% applied twice daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle cream applied twice daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CB-03-01 cream, 1%</intervention_name>
    <description>CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.</description>
    <arm_group_label>CB-03-01 cream</arm_group_label>
    <other_name>cortexolone 17α-propionate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle cream</intervention_name>
    <description>Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.</description>
    <arm_group_label>Vehicle cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is male or non-pregnant female, 9 years of age or older. Females must be
             post-menopausal, surgically sterile, or using highly effective birth control methods.
             Women of child-bearing potential must have a negative urine pregnancy test (UPT) at
             the Screening/Baseline Visit.

          2. Subject has provided written and verbal informed consent/assent. A subject under 18
             years of age must provide written informed assent and be accompanied by the parent or
             legal guardian at the time of assent/consent signing.

          3. Subject has an Investigator's Global Assessment (IGA) score of 3 (moderate) or 4
             (severe) [0 (clear) to 4 (severe) scale].

          4. Subject has facial acne vulgaris with at least 30 to a maximum of 75 inflammatory
             lesions (papules, pustules, and nodules) and 30 to a maximum of 100 non-inflammatory
             lesions (open and closed comedones).

          5. Subject and parent/guardian (if applicable) are willing to comply with study
             instructions and return to the clinic for required visits.

          6. Subject has used the same type and brand of make-up, other facial products (exclusive
             of RX/OTC acne cleansers) and hair products (e.g., shampoo, gel, hair spray, mousse,
             etc.) for at least one (1) month prior to the Baseline Visit and agrees to continue
             his/her other general skin and hair care products and regimen for the entire study.

        Exclusion Criteria:

          1. Subject is pregnant, lactating, or is planning to become pregnant during the study.

          2. Subject has any skin pathology or condition that could interfere with the evaluation
             of the test products or requires the use of interfering topical or systemic therapy.

          3. Subject has greater than two (2) facial nodules.

          4. Subject has nodulocystic acne.

          5. Subject has any condition which, in the investigator's opinion, would make it unsafe
             for the subject to participate in this research study.

          6. Subject is currently enrolled in an investigational drug or device study.

          7. Subject has received an investigational drug or has been treated with an
             investigational device within 30 days prior to the initiation of treatment (Baseline).

          8. Subject has facial hair that could interfere with the study assessments in the opinion
             of the investigator.

          9. Subject and parent/guardian (if applicable) are unable to communicate or cooperate
             with the investigator due to language problems, poor mental development, or impaired
             cerebral function.

         10. Subject may be unreliable for the study including subjects who engage in excessive
             alcohol intake or drug abuse, or subjects who are unable to return for scheduled
             follow-up visits.

         11. Subject has known hypersensitivity or previous allergic reaction to any of the active
             or inactive components of the test articles.

         12. Subject has the need or plans to be exposed to artificial tanning devices or excessive
             sunlight during the trial.

         13. Subject has used any of the prohibited topical anti-acne treatments or procedures
             prior to the study unless appropriate washout period is documented.

         14. Subject has used used any of the prohibited systemic anti-acne medications prior to
             the study unless appropriate washout period is documented.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrico Fragasso</last_name>
    <role>Study Director</role>
    <affiliation>Cassiopea S.p.A.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marietta Radona, MD</last_name>
    <email>acnestudy@therapeuticsinc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gary M. Petrus, MD PA</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center For Dermatology Clinical Research, Inc.</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vitiligo &amp; Pigmentation Institute of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>San Diego Sports Medicine and Family Health Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rady Childrens Hospital, Pediatric and Adolescent Dermatology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Funk</last_name>
      <phone>858-576-1700</phone>
      <phone_ext>4295</phone_ext>
    </contact>
    <investigator>
      <last_name>Lawrence Eichenfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern California Dermatology</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Swasdibutra</last_name>
      <phone>714-474-2173</phone>
      <email>swasdib@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jennifer Soung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Science Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Research Medical Clinic dba / Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Horizons Clinical Research Center, LLC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Savin Center, PC</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site 0190</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33434</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>561-487-7575</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Protocol, Inc.</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33437</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Site 0196</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>786-536-5755</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 0197</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>305-459-3578</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 0198</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>786-409-5439</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 0199</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33145</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>305-982-8349</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 0191</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33172</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>305-887-2252</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 0192</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33172</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>305-870-5999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 0195</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>305-702-1594</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tory Sullivan, M.D., P.A.</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Chockley</last_name>
      <phone>305-652-8600</phone>
      <email>achockley@leavittmgt.com</email>
    </contact>
    <investigator>
      <last_name>Tory Sullivan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Shafer</last_name>
      <phone>954-430-1097</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MOORE Clinical Research, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Causey</last_name>
      <phone>813-948-7550</phone>
      <email>lcausey@mooreclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Reginold Simmons, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedaPhase, Inc.</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mangieri, RN, CCRC</last_name>
      <phone>770-252-6900</phone>
      <email>kmangieri@medaphase.com</email>
    </contact>
    <investigator>
      <last_name>Mark R Ling, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shideler Clinical Research Center</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Indiana Clinical Trials Center</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>MediSearch Clinical Trials</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Center for Dermatology, Cosmetic &amp; Laser Surgery</name>
      <address>
        <city>Mount Kisco</city>
        <state>New York</state>
        <zip>10549</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>DermResearch Center of New York, Inc.</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Hennessy, LPN</last_name>
      <phone>631-689-1900</phone>
      <email>chennessy@drcny.com</email>
    </contact>
    <investigator>
      <last_name>Elyse Rafal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Dermatology and Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Pennsylvania State University and the Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omega Medical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joy Geer, RN</last_name>
      <phone>401-739-9350</phone>
      <email>Joy@omegamedicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>David Fried, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Dermatology, LLC</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>International Clinical Research - Tennessee LLC</name>
      <address>
        <city>Murfreesboro</city>
        <state>Tennessee</state>
        <zip>37130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Clinical Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westlake Dermatology Clinical Research Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78746</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alisha Rogers, CCRC</last_name>
      <phone>512-615-3193</phone>
      <email>alisha@westlakedermatology.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Friedmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bellaire Dermatology Associates</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>J&amp;S Studies, Inc.</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Lopez</last_name>
      <phone>713-500-8266</phone>
      <email>maria.d.lopez@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <phone>713-500-3073</phone>
    </contact_backup>
    <investigator>
      <last_name>Adelaide Hebert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Institute for Clinical Research, Inc.</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates of Tidewater, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Biggs, CRC</last_name>
      <phone>757-627-7446</phone>
      <email>jbiggs@crat.org</email>
    </contact>
    <investigator>
      <last_name>Duane Wombolt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Tyler</last_name>
      <phone>206-267-2101</phone>
      <email>styler@daseattle.com</email>
    </contact>
    <contact_backup>
      <phone>206-267-2100</phone>
    </contact_backup>
    <investigator>
      <last_name>Peter Jenkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mi Miao</last_name>
      <phone>509-343-3710</phone>
      <email>mi@premierclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>William Werschler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.usacnestudy.com</url>
    <description>Study Website</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2015</study_first_submitted>
  <study_first_submitted_qc>November 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2015</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acne</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

